92
F. Cheng
6. Lenneman CG, Sawyer DB (2016) Cardio-oncology, an update on cardiotoxicity of cancerrelated treatment. Circ Res 118(6):1008–1020
7. Han X, Zhou Y, Liu W (2017) Precision cardio-oncology, understanding the cardiotoxicity
of cancer therapy. NPJ Precis Oncol 1(1):31
8. Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR et al (2017) Risk of heart
failure with preserved ejection fraction in older women after contemporary radiotherapy for
breast cancer. Circulation 135(15):1388–1396
9. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al (2011) Adjuvant
trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283
10. Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N et al (2017) Highthroughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med 9(377):eaaf2584
11. Cheng F, Loscalzo J (2017) Autoimmune cardiotoxicity of cancer immunotherapy. Trends
Immunol 38(2):77–78
12. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y et al (2016)
Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med
375(18):1749–1755
13. Ranchoux B, Gunther S, Quarck R, Chaumais MC, Dorfmuller P, Antigny F et al (2015)
Chemotherapy-induced pulmonary hypertension, role of alkylating agents. Am J Pathol
185(2):356–371
14. Chien KR (2006) Herceptin and the heart–a molecular modifier of cardiac failure. N Engl J
Med 354(8):789–790
15. Cheng F (2018) In silico oncology drug repositioning and polypharmacology. Methods Mol
Biol 1878:243–261
16. Elkins JM, Fedele V, Szklarz M, Abdul Azeez KR, Salah E, Mikolajczyk J et al (2016) Comprehensive characterization of the published kinase inhibitor set. Nat Biotechnol 34(1):95–103
17. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10(2):130–137
18. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J (2015) Vascular and
metabolic implications of novel targeted cancer therapies, focus on kinase inhibitors. J Am
Coll Cardiol 66(10):1160–1178
19. Mullard A (2017) 2016 FDA drug approvals. Nat Rev Drug Discov 16(2):73–76
20. Loscalzo J, Barabasi AL, Silverman EK (2017) Network medicine, complex systems in human
disease and therapeutics. Publisher, Harvard University Press Publication Date 2/1/2017.
ISBN 9780674436534
21. Antman EM, Loscalzo J (2016) Precision medicine in cardiology. Nat Rev Cardiol
13(10):591–602
22. Greene JA, Loscalzo J (2017) Putting the patient back together—social medicine, network
medicine, and the limits of reductionism. N Engl J Med 377(25):2493–2499
23. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al (2006) Cardiotoxicity of
the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908–916
24. Distler JH, Distler O (2007) Cardiotoxicity of imatinib mesylate, an extremely rare phenomenon or a major side effect? Ann Rheum Dis 66(6):836
25. Cheng F, Hong H, Yang S, Wei Y (2017) Individualized network-based drug repositioning
infrastructure for precision oncology in the panomics era. Brief Bioinform 18(4):682–697
26. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G et al (2012) Prediction of drug-target interactions
and drug repositioning via network-based inference. PLoS Comput Biol 8(5):e1002503
27. Cheng F, Liu C, Lin CC, Zhao J, Jia P, Li WH et al (2015) A gene gravity model for the
evolution of cancer genomes, a study of 3000 cancer genomes across 9 cancer types. PLoS
Comput Biol 11(9):e1004497
28. Cheng F, Jia P, Wang Q, Lin CC, Li WH, Zhao Z (2014) Studying tumorigenesis through
network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol
Evol 31(8):2156–2169
F. Cheng
6. Lenneman CG, Sawyer DB (2016) Cardio-oncology, an update on cardiotoxicity of cancerrelated treatment. Circ Res 118(6):1008–1020
7. Han X, Zhou Y, Liu W (2017) Precision cardio-oncology, understanding the cardiotoxicity
of cancer therapy. NPJ Precis Oncol 1(1):31
8. Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR et al (2017) Risk of heart
failure with preserved ejection fraction in older women after contemporary radiotherapy for
breast cancer. Circulation 135(15):1388–1396
9. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al (2011) Adjuvant
trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283
10. Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N et al (2017) Highthroughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med 9(377):eaaf2584
11. Cheng F, Loscalzo J (2017) Autoimmune cardiotoxicity of cancer immunotherapy. Trends
Immunol 38(2):77–78
12. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y et al (2016)
Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med
375(18):1749–1755
13. Ranchoux B, Gunther S, Quarck R, Chaumais MC, Dorfmuller P, Antigny F et al (2015)
Chemotherapy-induced pulmonary hypertension, role of alkylating agents. Am J Pathol
185(2):356–371
14. Chien KR (2006) Herceptin and the heart–a molecular modifier of cardiac failure. N Engl J
Med 354(8):789–790
15. Cheng F (2018) In silico oncology drug repositioning and polypharmacology. Methods Mol
Biol 1878:243–261
16. Elkins JM, Fedele V, Szklarz M, Abdul Azeez KR, Salah E, Mikolajczyk J et al (2016) Comprehensive characterization of the published kinase inhibitor set. Nat Biotechnol 34(1):95–103
17. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10(2):130–137
18. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J (2015) Vascular and
metabolic implications of novel targeted cancer therapies, focus on kinase inhibitors. J Am
Coll Cardiol 66(10):1160–1178
19. Mullard A (2017) 2016 FDA drug approvals. Nat Rev Drug Discov 16(2):73–76
20. Loscalzo J, Barabasi AL, Silverman EK (2017) Network medicine, complex systems in human
disease and therapeutics. Publisher, Harvard University Press Publication Date 2/1/2017.
ISBN 9780674436534
21. Antman EM, Loscalzo J (2016) Precision medicine in cardiology. Nat Rev Cardiol
13(10):591–602
22. Greene JA, Loscalzo J (2017) Putting the patient back together—social medicine, network
medicine, and the limits of reductionism. N Engl J Med 377(25):2493–2499
23. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al (2006) Cardiotoxicity of
the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908–916
24. Distler JH, Distler O (2007) Cardiotoxicity of imatinib mesylate, an extremely rare phenomenon or a major side effect? Ann Rheum Dis 66(6):836
25. Cheng F, Hong H, Yang S, Wei Y (2017) Individualized network-based drug repositioning
infrastructure for precision oncology in the panomics era. Brief Bioinform 18(4):682–697
26. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G et al (2012) Prediction of drug-target interactions
and drug repositioning via network-based inference. PLoS Comput Biol 8(5):e1002503
27. Cheng F, Liu C, Lin CC, Zhao J, Jia P, Li WH et al (2015) A gene gravity model for the
evolution of cancer genomes, a study of 3000 cancer genomes across 9 cancer types. PLoS
Comput Biol 11(9):e1004497
28. Cheng F, Jia P, Wang Q, Lin CC, Li WH, Zhao Z (2014) Studying tumorigenesis through
network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol
Evol 31(8):2156–2169